Breaking News

Evotec Earns Janssen Milestone

January 12, 2016

Advances Alzheimer's target

Evotec AG has achieved an important milestone in its TargetAD Alzheimer's collaboration with Janssen Pharmaceuticals, transitioning a project into further drug discovery development.   
The companies entered the collaboration in October 2013 to develop new drugs for Alzheimer's disease. Janssen has the right to internalize selected targets and therapeutic candidates and progress them into preclinical and clinical development. Janssen funds target drug discovery research via a combination of defined research payments and progress-related milestones.
Dr. Cord Dohrmann, chief scientific officer of Evotec, said, "Despite the significant challenges in identifying and prosecuting novel targets in the field of Alzheimer's disease, our collaboration with Janssen continues to thrive as documented by this milestone. On the basis of an ever improving platform and an excellent team that is seamlessly integrated across both companies, we are confident that further progress will follow in 2016."
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer